Direct targeting of Bcl-2 family members is independent of p53 status since p53 lies upstream of the Bcl-2 pathway [348], which is especially relevant in osteosarcoma as most osteosarcoma tumours have p53 abnormalities [82]. Here, TP53 is linked to neoplasm.